Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/30/2023 | Cyclacel Pharmaceuticals, Inc. | CYCC | Grant | Common Stock | 21.2k | $0.00 | $0 | | 06/30/2023 |
06/30/2023 | Cyclacel Pharmaceuticals, Inc. | CYCC | Grant | Stock Option (right to buy) | 42.4k | $0.59 | $25k | | 06/30/2023 |
06/16/2022 | INFINITY PHARMACEUTICALS, INC. | INFI | Grant | Common Stock | 30.9k | $0.68 | $21k | | 06/16/2022 |
06/16/2022 | INFINITY PHARMACEUTICALS, INC. | INFI | Grant | Stock Option(right to buy) | 45k | $0.68 | $30.6k | | 06/16/2022 |
09/07/2021 | INFINITY PHARMACEUTICALS, INC. | INFI | Grant | Stock Option (right to buy) | 60k | $3.75 | $225k | | 09/07/2021 |
06/15/2021 | Cyclacel Pharmaceuticals, Inc. | CYCC | Grant | Common Stock | 2.4k | $0.00 | $0 | | 06/15/2021 |
06/15/2021 | Cyclacel Pharmaceuticals, Inc. | CYCC | Grant | Common Stock | 1.2k | $0.00 | $0 | | 06/15/2021 |
06/15/2021 | Cyclacel Pharmaceuticals, Inc. | CYCC | Grant | Stock Option (right to buy) | 4.7k | $6.69 | $31.8k | | 06/15/2021 |
06/15/2021 | Cyclacel Pharmaceuticals, Inc. | CYCC | Grant | Stock Option (right to buy) | 2.4k | $6.69 | $15.9k | | 06/15/2021 |
12/17/2020 | Cyclacel Pharmaceuticals, Inc. | CYCC | Grant | | 5.2k | $4.13 | $21.5k | | 12/17/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 65k | $5.48 | $356.2k | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 314k | $3.68 | $1.2M | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 140k | $6.70 | $938k | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 12.6k | $7.95 | $100k | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 21.4k | $2.51 | $53.7k | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 106.5k | $2.57 | $273.7k | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 130k | $1.53 | $198.9k | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 108k | $1.79 | $193.3k | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 147k | $1.16 | $170.5k | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Other | Common Stock | 289.8k | $20.00 | $5.8M | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 40k | $2.48 | $99.2k | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 107.9k | $1.75 | $188.8k | | 01/16/2020 |
01/16/2020 | ARQULE INC | ARQL | Disposition | Stock Option (Right to Buy) | 260k | $0.95 | $247k | | 01/16/2020 |
12/18/2019 | ARQULE INC | ARQL | Exercise | Stock Options (Right to Buy) | 100k | $1.79 | $179k | | 12/18/2019 |
12/18/2019 | ARQULE INC | ARQL | Payment of Exercise | Common Stock | 178.5k | $20.11 | $3.6M | | 12/18/2019 |
12/18/2019 | ARQULE INC | ARQL | Exercise | Stock Options (Right to Buy) | 90k | $3.42 | $307.8k | | 12/18/2019 |
12/18/2019 | ARQULE INC | ARQL | Exercise | Stock Options (Right to Buy) | 96.9k | $7.95 | $770.5k | | 12/18/2019 |
12/18/2019 | ARQULE INC | ARQL | Exercise | Stock Options (Right to Buy) | 64.1k | $2.51 | $161k | | 12/18/2019 |
03/12/2019 | ARQULE INC | ARQL | Grant | Employee Stock Options | 130k | $0.95 | $123.5k | | 03/12/2019 |
01/15/2019 | ARQULE INC | ARQL | Grant | Employee Stock Options | 314k | $3.68 | $1.2M | | 01/15/2019 |
07/23/2018 | ARQULE INC | ARQL | Grant | Employee Stock Options | 65k | $5.48 | $356.2k | | 07/23/2018 |
06/13/2018 | ARQULE INC | ARQL | Exercise | Stock Options (Right to Buy) | 200k | $3.62 | $724k | | 06/13/2018 |
06/13/2018 | ARQULE INC | ARQL | Payment of Exercise | Common Stock | 148.6k | $5.18 | $769.6k | | 06/13/2018 |
05/08/2018 | ARQULE INC | ARQL | Grant | Employee Stock Options | 40k | $2.48 | $99.2k | | 05/08/2018 |
01/16/2018 | ARQULE INC | ARQL | Grant | Employee Stock Options | 107.9k | $1.75 | $188.8k | | 05/08/2018 |
|